New Distinction in Immunoglobulin Therapy

Setting the standard in safe, evidence-based immunoglobulin therapy

Developed in collaboration with the Immunoglobulin National Society (IgNS), the industry’s first Distinction in Immunoglobulin (Ig) Therapy recognizes organizations that demonstrate advanced clinical, operational, and safety practices in the delivery of immunoglobulin across care settings.

This distinction is grounded in the IgNS Standards of Practice—a comprehensive, evidence-based framework for the safe and effective use of immunoglobulin therapy.

The result? A new step forward in improving quality, credibility, and patient outcomes in immunoglobulin therapy.

Interested in the Distinction?

Complete the form below to receive additional details and future updates about the Ig Therapy Distinction.

Why it matters

  • For patients: Promotes safer, more consistent immunoglobulin therapy and improved outcomes.
  • For care teams: Reinforces collaboration, clinical appropriateness, and shared accountability.
  • For pharmacies: Demonstrates leadership in Ig therapy delivery and alignment with evidence-based best practices.

Who is eligible

To apply, organizations must be ACHC-accredited—or seeking accreditation—in one of the following programs:

  • Infusion Pharmacy

  • Infusion Pharmacy (no 797)

  • Specialty Pharmacy

  • AIC/AIS

“AOM is honored to be one of the first in the nation to earn the Distinction in Ig Therapy through ACHC. This achievement affirms our commitment to patients, providers, and partners that our immunoglobulin therapy program offers exceptional clinical care at the highest practice standards. It also reflects our broader vision to lead the advancement of care, improve therapeutic outcomes, and redefine the patient journey in pursuit of better health.”

—John Vlahopoulos, PharmD, MBA
Chief Clinical Officer, AOM Infusion